Fig. 2. Endogenous bcd mRNA deadenylation is delayed developmentally in pum^– mutants. (A) The bcd 3'UTR and PAT assay internal control (bcd, to scale) with 1 1/2 NREs (arrow) and bcd-specific oligo priming site (PAT_bcd). (B) Internally controlled bcd PAT assay profiles from wild type (lanes 1-9) and pum^– (lanes 1'-9') samples including ovarian (1,1') and embryonic (2-9,2'-9') RNAs (20°C). C1, cDNA synthesis control (only internal control RNA); C2, PCR control (no template). Equal volumes of the final reactions were resolved on acrylamide-urea gel and autoradiographed. ‘m’, ³²P-labeled marker. (C) osk PAT assay profile in wild type and pum^– mutants. The same cDNAs as B were amplified with an osk-specific primer (Sallés et al., 1994). osk deadenylation does not change noticeably in pum^– mutants. We observed a slight increase in osk stability (8-9 versus 8'-9'). C1, bcd cDNA control; C2, osk PCR control (no template).